Literature DB >> 24443000

Cancer-related fatigue: can it be due to adrenal suppression secondary to high-dose steroids used as antiemetic?

Orhan Onder Eren1, Mehmet Akif Ozturk, Basak Oyan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24443000     DOI： 10.1007/s00520-014-2124-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  8 in total

1.  Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment.

Authors:  C Henzen; A Suter; E Lerch; R Urbinelli; X H Schorno; V A Briner
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

2.  Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function.

Authors:  A W Meikle; F H Tyler
Journal:  Am J Med       Date:  1977-08       Impact factor: 4.965

Review 3.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

4.  A pilot study of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients.

Authors:  Hye-Suk Han; Young Kwang Shim; Jeong Eun Kim; Hyun-Jung Jeon; Sung-Nam Lim; Tae-Keun Oh; Ki Hyeong Lee; Seung Taik Kim
Journal:  Support Care Cancer       Date:  2011-08-18       Impact factor: 3.603

Review 5.  Fatigue associated with cancer and its treatment.

Authors:  Gary R Morrow; Paul L R Andrews; Jane T Hickok; Joseph A Roscoe; Sara Matteson
Journal:  Support Care Cancer       Date:  2001-08-15       Impact factor: 3.603

6.  Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer.

Authors:  Sriram Yennurajalingam; Susan Frisbee-Hume; J Lynn Palmer; Marvin O Delgado-Guay; Janet Bull; Alexandria T Phan; Nizar M Tannir; Jennifer Keating Litton; Akhila Reddy; David Hui; Shalini Dalal; Lisa Massie; Suresh K Reddy; Eduardo Bruera
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

7.  Symptoms in advanced cancer: relationship to endogenous cortisol levels.

Authors:  Staffan Lundström; Carl Johan Fürst
Journal:  Palliat Med       Date:  2003-09       Impact factor: 4.762

8.  The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer.

Authors:  H R Scott; D C McMillan; L M Forrest; D J F Brown; C S McArdle; R Milroy
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640
  8 in total
  2 in total

1.  Cancer-related fatigue, the role of adrenal suppression and steroids: reply to the comments of Eren et al.

Authors:  Sriram Yennurajalingam; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2014-07-31       Impact factor: 3.603

2.  Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence.

Authors:  Luigi Celio; Erminio Bonizzoni; Emma Zattarin; Paolo Codega; Filippo de Braud; Matti Aapro
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.